Avstera Therapeutics
- Biotech or pharma, therapeutic R&D
Avstera is a Pennsylvania based biotech developing novel, best-in-class highly selective oral HDAC6 inhibitors targeting a broad range of diseases including obesity/cardiometabolic, and other related indications. Lead is Phase I ready with several candidates approaching IND.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}